Outcome measures by treatment arm
| CPE | Erlotinib monotherapy | HR (95% CI) | |
| Patients randomised | 11 | 11 | |
| PFS months, median (95% CI) | 8.8 (4.2–18.8) | 10.3 (7.1–15.5) | 0.78 (0.32–1.91)# |
| Overall survival, median (95% CI) | 30.9 (18.5–61.9) | 17.2 (11.5–45.5) | 0.66 (0.27–1.65) |
| 1-year overall survival, % (95% CI) | 81.8 (48.2–97.7) | 72.7 (39.0–94.0) | |
| ORR, % (95% CI) | 64 (31–89) | 55 (23–83) | |
| Complete response | 1 (9) | 1 (9) | |
| Partial response | 6 (54) | 5 (46) | |
| Stable disease | 4 (36) | 5 (46) | |
| Duration of response in months, median (95% CI) | 10.8 (7.3–31.2) | 8.0 (5.5–8.7) | 0.43 (0.12–1.47) |
Data are presented as n or n (%), unless otherwise stated. CPE: cisplatin-pemetrexed-erlotinib; HR: hazard ratio; PFS: progression-free survival; ORR: overall response rate. #: after compensating for numbers of days receiving erlotinib HR 0.32, 95% CI 0.10–1.01; p=0.05.